Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Study finds most billion-dollar AI startups rarely publish research

Study finds most billion-dollar AI startups rarely publish research

New Capabilities

A bioRxiv analysis of 317 AI unicorns finds more than half have never led a scientific paper

2 days ago: Study finds most AI unicorns rarely publish

Overview

The companies claiming to reinvent science are mostly absent from the scientific record. A study covered by Science on July 27, 2026, found that more than half of the world's AI unicorns have never led a single peer-reviewed paper or preprint.

The 317 startups studied are worth over $1 billion each and promise to remake drug discovery, coding, and research itself. Together they produced just one in every 1,000 AI papers published in 2025. When they do publish, a tiny group dominates: the top 5% of firms account for more than 90% of all citations.

Why it matters

If the labs building the most powerful AI don't publish, outside scientists can't independently check what these systems do, how safe they are, or how much energy they burn.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

317
AI unicorns studied
Billion-dollar AI startups tracked from 1998 to 2025.
>50%
Never led a paper
Share of firms that never produced a first- or last-author publication.
~40%
OpenAI's citation share
One company accounts for roughly 40% of all citations in the data set.
2,077
Total publications found
1,389 peer-reviewed papers and 688 preprints across all 317 firms.
1 in 1,000
Share of 2025 AI papers
All unicorns combined produced about one of every thousand AI papers last year.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 3 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

August 2005 July 2026

3 events Latest: 2 days ago
  1. Study finds most AI unicorns rarely publish

    Latest Study

    A bioRxiv preprint reports that more than half of 317 AI unicorns never led a paper, and that all combined produced one in 1,000 AI papers in 2025.

  2. OpenAI founded

    Background

    The lab launches with an early emphasis on open research, later shifting toward technical reports and blog posts.

  3. Ioannidis publishes 'Why Most Published Research Findings Are False'

    Background

    The paper becomes a foundational text in metascience, the study of how research succeeds and fails.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

July 2021

AlphaFold open release (2021)

DeepMind published its protein-structure predictor AlphaFold in Nature and released the code and a database of predicted structures. Outside scientists could check the work and build on it directly.

Then

Researchers worldwide used the predictions in labs within months.

Now

The open release became a reference point for what corporate AI can contribute to science when firms publish fully.

Why this matters now

It is the counterexample the new study implies: full publication let the whole field verify and extend the work. Most unicorns don't do this.

2000-2001

Human Genome Project vs. Celera (2000)

A public consortium and the private firm Celera raced to sequence the human genome. The public effort released data openly; Celera sought to commercialize parts of it. The clash centered on who could access and reuse the data.

Then

The two sides announced a joint completion in 2000, but access terms differed.

Now

Open genome data became the norm and seeded a large research industry.

Why this matters now

It shows the recurring tension between commercial secrecy and open science, the same tension the AI publishing gap now raises.

Sources

(2)